Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 11/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 10/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 10/20 | 0.54 |
| ▸ | PTGIR | P43119 | 3/20 | 0.49 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.45 |
| ▸ | UNG | P13051 | 3/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743095 | 0.91 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13062961 | 0.80 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13017196 | 0.77 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| Hydrochloric Acid SCHEMBL4692792 | 0.76 | ADRA2A (0.78) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL9330419 | 0.74 | ESR1 (0.61) | ADRA2AADRA2BADRA2CUNG | |
| SCHEMBL60134 | 0.74 | ESR1 (0.61) | ADRA2AADRA2BADRA2CUNG | |
| SCHEMBL284616 | 0.74 | ESR1 (0.61) | ADRA2AADRA2BADRA2CUNG | |
| SCHEMBL2391508 | 0.74 | ESR1 (0.61) | ADRA2AADRA2BADRA2CUNG | |
| SCHEMBL294666 | 0.74 | ESR1 (0.61) | ADRA2AADRA2BADRA2CUNG | |
| SCHEMBL9330410 | 0.74 | ESR1 (0.61) | ADRA2AADRA2BADRA2CUNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 722 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391729-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20240199709-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC (US) | 2024-06-20 | — | — | US | claimed |
| US-11905315-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2024-02-20 | — | — | US | claimed |
| US-20210179672-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | GENISYS CREDIT UNION | 2021-06-17 | — | — | US | claimed |
| EP-2533633-B1 | FUNGICIDAL MIXTURES | LANXESS DISTRIB GMBH (DE) | 2017-02-01 | — | — | EP | claimed |
| WO-2016044655-A2 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC. (US) | 2016-03-24 | — | — | WO | claimed |
| US-20130195997-A1 | FUNGICIDAL MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| EP-2460408-A1 | Nematicidal compositions | deVGen N.V. (BE) | 2012-06-06 | — | — | EP | claimed |
| US-20110319435-A1 | FUNGICIDE MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2011-12-29 | — | — | US | claimed |
| EP-2315522-A2 | FORMATE-CONTAINING FUNGICIDE MIXTURES | LANXESS Distribution GmbH (DE) | 2011-05-04 | — | — | EP | claimed |
| EP-2153720-A1 | Fungicide mixtures comprising formate | LANXESS Distribution GmbH (DE) | 2010-02-17 | — | — | EP | claimed |
| WO-2010015635-A2 | FUNGICIDE MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
| US-12630484-B2 | Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes | SPOGEN BIOTECH INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12599141-B2 | Rod-shaped plant viral nanoparticles or virus-like particles for agricultural applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-12599649-B2 | Bioactive polypeptides for improvements in plant protection, growth and productivity | SPOGEN BIOTECH INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250388630-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-1998003495-A1 | DIHYDROFURAN CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003486-A1 | 1,3-DIMETHYL-5-FLUORO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MICROBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-29 | — | — | WO | disclosed |
| WO-1997047606-A1 | ARYLOXYACRYLIC ACID ESTERS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997047589-A1 | AMINOPHTHALIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630484-B2 | Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes | ADA, RNGTT, GNPDA1 | ADRA2A 2693/4885ADRA2B 2777/4885ADRA2C 2639/4885 |
| US-12599649-B2 | Bioactive polypeptides for improvements in plant protection, growth and productivity | MAX, VIP, MRTO4 | ADRA2A 3181/4885ADRA2B 3352/4885ADRA2C 3548/4885 |
| US-20250388630-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | MAX, SEC62, GHITM | ADRA2A 4835/4885ADRA2B 4251/4885ADRA2C 4810/4885 |
| US-12599141-B2 | Rod-shaped plant viral nanoparticles or virus-like particles for agricultural applications | PRNP, PCNP, VIM | ADRA2A 3412/4885ADRA2B 4142/4885ADRA2C 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.